Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer
August 18, 2025 – Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical – Anocca, T-cell immunotherapies, TCR-T cell, clinical trials, financing
- Financing supports execution of early-stage clinical trials for Anocca’s lead programme VIDAR-1, powered by the Company’s leading-edge R&D platform, to target pancreatic cancer
- VIDAR-1 is the first non-viral gene-edited TCR-T cell therapy in Europe with recruitment open.
18 August 2025 — Södertälje, Sweden — Anocca, a leading clinical-stage T-cell immunotherapy company, has successfully raised SEK ~440 million (USD ~46 million) in financing. The additional capital will be used to drive the continued progress of VIDAR-1, Anocca’s gene-edited TCR-T cell therapies targeting mutant KRAS in pancreatic cancer, through early-stage clinical development, as well as progress Anocca’s preclinical pipeline. The financing was led by Mellby Gård with strong support from AMF, Ramsbury and existing shareholders, alongside new investors.
Recruitment is now open for Phase I of the multi-centre trial of VIDAR-1, which is being conducted at leading university hospitals across Sweden, Denmark, Germany and The Netherlands.
Reagan Jarvis, co-founder and Chief Executive Officer of Anocca, said: “We thank our investors for their strong and continued support as we advance our first TCR-T cell therapy products into the clinic. The team has built a unique discovery platform and in-house manufacturing capability, and we are now excited to see the first products reaching patients with high unmet need.”
Johan Andersson, Chairman of Mellby Gård, commented: “We have been invested in Anocca throughout its preclinical development and are pleased to see the Company transition into a clinical stage biotech. We look forward to seeing Anocca help patients that have limited treatment options today with their innovative approach to T-cell therapies”.
SEB Corporate Finance acted as financial advisor to Anocca on the finalisation of the transaction, and Mannheimer Swartling and HWF Advokater have acted as legal advisors.
About Anocca
Anocca is a fully integrated clinical-stage biopharmaceutical company that develops libraries of T-cell receptor-engineered T cell (TCR-T) therapies to redefine the treatment of solid tumours and other difficult to treat diseases, including infectious and autoimmune diseases. The company has built a unique discovery engine that uses programmable human cells to recreate and manipulate T cell immunity. These proprietary technologies enable scaling of TCR-T cell therapy development, allowing the systematic generation of libraries of products that represent personalised treatments for the broad patient populations. Anocca currently has the broadest pipeline of TCR-T oncology cell therapy treatments. Anocca operates an advanced research and development infrastructure, underpinned by a custom software ecosystem, AnoccaOS, and an in-house cGMP manufacturing and process development facility. Anocca’s TCR-T cell therapies are novel discoveries from its platform and manufactured using non-viral gene editing technology at Anocca’s facilities in Södertälje, Sweden. 130+ staff from 40+ nations work at Anocca. Visit: anocca.com.
